Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Clinical trial NCT02437500 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT02437500
- Sponsor
- Seres Therapeutics, Inc.
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.